Treatment of hirsutism in polycystic ovary syndrome with bromocriptine.
The value of bromocriptine in the treatment of hirsutism in polycystic ovary syndrome (PCO) was assessed subjectively and photographically in a double-blind trial in 22 women studied for 1 year. Menstrual frequency was recorded. Circulating concentrations of oestradiol, oestrone, testosterone, androstenedione, and sex hormone binding globulin (SHBG) were determined before treatment and after 6 and 12 months therapy. On the same occasions gonadotrophin concentrations (mean of 24 samples) and their response to 100 micrograms LHRH were determined. No evidence was found to support a therapeutic role for bromocriptine in the treatment of hirsutism or menstrual regulation in PCO. No biochemical changes were seen specific to bromocriptine therapy.
D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D012739:Gonadal Steroid Hormones / Q000032:analysis; D006628:Hirsutism / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000150:complications*; D011897:Random Allocation
D012739:Gonadal Steroid Hormones; D001971:Bromocriptine